Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/ K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study

Autor: Long, G.V. Flaherty, K.T. Stroyakovskiy, D. Gogas, H. Levchenko, E. de Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Chiarion-Sileni, V. Lebbe, C. Mandalà, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B.A.G. Hansson, J. Utikal, J. Ferraresi, V. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. Davies, M.A. Lane, S.R. Legos, J.J. Mookerjee, B. Grob, J.-J.

Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::69131d425fb12c2003f5f42b2bb9adbd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108520

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

Autor: Long, G.V. Stroyakovskiy, D. Gogas, H. Levchenko, E. De Braud, F. Larkin, J. Garbe, C. Jouary, T. Hauschild, A. Grob, J.J. Chiarion Sileni, V. Lebbe, C. Mandalà, M. Millward, M. Arance, A. Bondarenko, I. Haanen, J.B.A.G. Hansson, J. Utikal, J. Ferraresi, V. Kovalenko, N. Mohr, P. Probachai, V. Schadendorf, D. Nathan, P. Robert, C. Ribas, A. DeMarini, D.J. Irani, J.G. Casey, M. Ouellet, D. Martin, A.-M. Le, N. Patel, K. Flaherty, K.

Results The median progression-free survival was 9.3 months in the dabrafenib-trametinib group and 8.8 months in the dabrafenib-only group (hazard ratio for progression or death in the dabrafenib-trametinib group, 0.75; 95% confidence interval [CI],

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::cd4ca521e83161a6f0f66f794868224e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3110418

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Autor: Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia. Electronic address: georgina.long@sydney.edu.au., Stroyakovskiy D; Moscow City Oncology Hospital, Moscow, Russia., Gogas H; Department of Medicine, University of Athens, Medical School, Athens, Greece., Levchenko E; Petrov Research Institute of Oncology, Saint Petersburg, Russia., de Braud F; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Larkin J; Royal Marsden Hospital, London, UK., Garbe C; Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany., Jouary T; Department of Dermatology, Hôpital Saint André, CHU Bordeaux, Bordeaux, France., Hauschild A; University Hospital Schleswig-Holstein, Kiel, Germany., Grob JJ; Aix-Marseille University and APHM Hospital CHU Timone, Marseille, France., Chiarion-Sileni V; Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padua, Italy., Lebbe C; APHP Dermatology CIC Hôpital Saint Louis, University Paris Diderot, INSERM U976, Paris, France., Mandalà M; Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy., Millward M; Sir Charles Gairdner Hospital, Hospital Avenue, Perth, WA, Australia., Arance A; Department of Medical Oncology, Hospital Clinic and Translational Genomics and Targeted Therapeutics in Solid Tumors, Barcelona, Spain., Bondarenko I; Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine., Haanen JB; Netherlands Cancer Institute, Amsterdam, Netherlands., Hansson J; Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden., Utikal J; University Medical Center Mannheim, Heidelberg University, Mannheim, Germany; German Cancer Research Center, Heidelberg, Germany., Ferraresi V; Istituto Nazionale Tumori Regina Elena, Rome, Italy., Kovalenko N; Volograd Regional Oncology Dispensary #3, Volzhsky, Russia., Mohr P; Elbe Klinikum Stade, Stade, Germany., Probachai V; Dnipropetrovsk Clinical Oncology Center of Dnipropetrovsk State Council, Dnipropetrovsk, Ukraine., Schadendorf D; University Hospital Essen, Essen, Germany., Nathan P; Mount Vernon Cancer Centre, Northwood, UK., Robert C; Gustave Roussy, Villejuif-Paris-Sud, France; Paris Sud University, Le Kremlin Bicêtre, France., Ribas A; David Geffen School of Medicine, UCLA, Los Angeles, CA, USA., DeMarini DJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Irani JG; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Swann S; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Legos JJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Jin F; Merck & Co, Kenilworth, NJ, USA., Mookerjee B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Flaherty K; Massachusetts General Hospital Cancer Center, Boston MA, USA.

Publikováno v: Lancet (London, England) [Lancet] 2015 Aug 01; Vol. 386 (9992), pp. 444-51. Date of Electronic Publication: 2015 May 31.

WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.

Autor: Coupe, Nicholas^1,2 (AUTHOR) nicholas.coupe@ouh.nhs.uk, Guo, Lina¹ (AUTHOR), Bridges, Esther¹ (AUTHOR), Campo, Leticia¹ (AUTHOR), Espinosa, Olivia³ (AUTHOR), Colling, Richard³ (AUTHOR), Marshall, Andrea⁴ (AUTHOR), Nandakumar, Ashwin⁵ (AUTHOR), van Stiphout, Ruud¹ (AUTHOR), Buffa, Francesca M.¹ (AUTHOR), Corrie, Pippa G.⁶ (AUTHOR), Middleton, Mark R.^1,2 (AUTHOR), Macaulay, Valentine M.^2,5 (AUTHOR) valentine.macaulay@nds.ox.ac.uk

Publikováno v: Cellular Oncology (2211-3428). Apr2023, Vol. 46 Issue 2, p391-407. 17p.